Last reviewed · How we verify
Carbaphen (PHENICARBAZIDE)
Carbaphen, marketed as Phenicarbazide, is an anti-allergenic drug primarily indicated for allergic rhinitis. Its key strength lies in its mechanism of action, which effectively modulates the body's response to allergens and irritants, reducing inflammation and congestion in the nasal passages. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PHENICARBAZIDE |
|---|---|
| Drug class | phenicarbazide |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Allergic rhinitis
- Common cold
- Cough
- Nasal congestion
- Nasal discharge
- Vasomotor rhinitis
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbaphen CI brief — competitive landscape report
- Carbaphen updates RSS · CI watch RSS